| Year |
Citation |
Score |
| 2024 |
Mayer BT, Zhang L, deCamp AC, Yu C, Sato A, Angier H, Seaton KE, Yates N, Ledgerwood JE, Mayer K, Caskey M, Nussenzweig M, Stephenson K, Julg B, Barouch DH, et al. Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics. 16. PMID 38794258 DOI: 10.3390/pharmaceutics16050594 |
0.302 |
|
| 2024 |
Frank I, Li SS, Grunenberg N, Overton ET, Robinson ST, Zheng H, Seaton KE, Heptinstall JR, Allen MA, Mayer KH, Culver DA, Keefer MC, Edupuganti S, Pensiero MN, Mehra VL, et al. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. The Lancet. Hiv. 11: e285-e299. PMID 38692824 DOI: 10.1016/S2352-3018(24)00036-5 |
0.343 |
|
| 2024 |
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, Omar FL, Kee JJ, Bekker LG, Laher F, Naicker N, Jani I, Mgodi NM, Hunidzarira P, Sebe M, Miner MD, Polakowski L, ... ... Seaton KE, et al. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. Plos Medicine. 21: e1004360. PMID 38502656 DOI: 10.1371/journal.pmed.1004360 |
0.356 |
|
| 2024 |
Walsh SR, Gay CL, Karuna ST, Hyrien O, Skalland T, Mayer KH, Sobieszczyk ME, Baden LR, Goepfert PA, Del Rio C, Pantaleo G, Andrew P, Karg C, He Z, Lu H, ... ... Seaton K, et al. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087). Medrxiv : the Preprint Server For Health Sciences. PMID 38260276 DOI: 10.1101/2024.01.10.23299799 |
0.327 |
|
| 2023 |
Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, ... ... Seaton KE, et al. High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nature Communications. 14: 8299. PMID 38097552 DOI: 10.1038/s41467-023-43384-y |
0.31 |
|
| 2023 |
Sobieszczyk ME, Mannheimer S, Paez CA, Yu C, Gamble T, Theodore DA, Chege W, Yacovone M, Hanscom B, Heptinstall J, Seaton KE, Zhang L, Miner MD, Eaton A, Weiner JA, et al. Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. The Lancet. Hiv. 10: e653-e662. PMID 37802566 DOI: 10.1016/S2352-3018(23)00140-6 |
0.335 |
|
| 2023 |
Chirenje ZM, Laher F, Dintwe O, Muyoyeta M, deCamp AC, He Z, Grunenberg N, Laher Omar F, Seaton KE, Polakowski L, Woodward Davis AS, Maganga L, Baden LR, Mayer K, Kalams S, et al. Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. The Journal of Infectious Diseases. PMID 37795976 DOI: 10.1093/infdis/jiad434 |
0.353 |
|
| 2023 |
Tieu HV, Karuna S, Huang Y, Sobieszczyk ME, Zheng H, Tomaras GD, Montefiori DC, Shen M, DeRosa S, Cohen K, Isaacs MB, Regenold S, Heptinstall J, Seaton KE, Sawant S, et al. Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US. Vaccine. PMID 37679276 DOI: 10.1016/j.vaccine.2023.07.046 |
0.311 |
|
| 2023 |
Seaton KE, Huang Y, Karuna S, Heptinstall JR, Brackett C, Chiong K, Zhang L, Yates NL, Sampson M, Rudnicki E, Juraska M, deCamp AC, Edlefsen PT, Mullins JI, Williamson C, et al. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. Ebiomedicine. 93: 104590. PMID 37300931 DOI: 10.1016/j.ebiom.2023.104590 |
0.333 |
|
| 2022 |
Mayer-Blackwell K, Johnson AM, Potchen N, Minot SS, Heptinstall J, Seaton K, Sawant S, Shen X, Tomaras GD, Fiore-Gartland A, Kublin JG. Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines. Frontiers in Immunology. 13: 983313. PMID 36311720 DOI: 10.3389/fimmu.2022.983313 |
0.303 |
|
| 2022 |
Huang Y, Zhang Y, Seaton KE, De Rosa S, Heptinstall J, Carpp LN, Randhawa AK, McKinnon LR, McLaren P, Viegas E, Gray GE, Churchyard G, Buchbinder SP, Edupuganti S, Bekker LG, et al. Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. Ebiomedicine. 84: 104271. PMID 36179551 DOI: 10.1016/j.ebiom.2022.104271 |
0.317 |
|
| 2022 |
Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, Giorgi EE, Korber B, Edlefsen PT, Rossenkhan R, Juraska M, Rudnicki E, Kochar N, Huang Y, Carpp LN, ... ... Seaton KE, et al. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nature Medicine. PMID 35995954 DOI: 10.1038/s41591-022-01953-6 |
0.341 |
|
| 2022 |
Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, Heptinstall J, Laher Omar F, Cohen K, De Rosa SC, Zhang L, Yates NL, Sarzotti-Kelsoe M, Seaton KE, Laher F, et al. Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk. The Journal of Infectious Diseases. PMID 35758878 DOI: 10.1093/infdis/jiac260 |
0.352 |
|
| 2021 |
Tomalka JA, Pelletier AN, Fourati S, Latif MB, Sharma A, Furr K, Carlson K, Lifton M, Gonzalez A, Wilkinson P, Franchini G, Parks R, Letvin N, Yates N, Seaton K, et al. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. Nature Immunology. PMID 34556879 DOI: 10.1038/s41590-021-01026-9 |
0.342 |
|
| 2021 |
Wesley MS, Chiong KT, Seaton KE, Arocena CA, Sawant S, Hare J, Hernandez K, Rojas M, Heptinstall J, Beaumont D, Crisafi K, Nkolola J, Barouch DH, Sarzotti-Kelsoe M, Tomaras GD, et al. Validation of a Triplex Pharmacokinetic Assay for Simultaneous Quantitation of HIV-1 Broadly Neutralizing Antibodies PGT121, PGDM1400, and VRC07-523-LS. Frontiers in Immunology. 12: 709994. PMID 34504492 DOI: 10.3389/fimmu.2021.709994 |
0.334 |
|
| 2021 |
Huang Y, Seaton KE, Casapia M, Polakowski L, De Rosa SC, Cohen K, Yu C, Elizaga M, Paez C, Miner MD, Kelley CF, Maenza J, Keefer M, Lama JR, Sobieszczyk M, et al. AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period. Vaccine. PMID 34229888 DOI: 10.1016/j.vaccine.2021.06.066 |
0.32 |
|
| 2021 |
Astronomo RD, Lemos MP, Narpala SR, Czartoski J, Ballweber Fleming L, Seaton KE, Prabhakaran M, Huang Y, Lu Y, Westerberg K, Zhang L, Gross MK, Hural J, Tieu HV, Baden LR, et al. Rectal and vaginal tissue from intravenous VRC01 recipients show protection against ex vivo HIV-1 challenge. The Journal of Clinical Investigation. PMID 34166231 DOI: 10.1172/JCI146975 |
0.33 |
|
| 2021 |
Seaton KE, Deal A, Han X, Li SS, Clayton A, Heptinstall J, Duerr A, Allen MA, Shen X, Sawant S, Yates NL, Spearman P, Churchyard G, Goepfert PA, Maenza J, et al. Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans. Npj Vaccines. 6: 56. PMID 33859204 DOI: 10.1038/s41541-021-00305-8 |
0.352 |
|
| 2020 |
Palli R, Seaton KE, Piepenbrink MS, Hural J, Goepfert PA, Laher F, Buchbinder SP, Churchyard G, Gray GE, Robinson HL, Huang Y, Janes H, Kobie JJ, Keefer MC, Tomaras GD, et al. Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. Scientific Reports. 10: 13031. PMID 32747654 DOI: 10.1038/S41598-020-69007-W |
0.319 |
|
| 2020 |
Zhao LP, Fiore-Gartland A, Carpp LN, Cohen KW, Rouphael N, Fleurs L, Dintwe O, Zhao M, Moodie Z, Fong Y, Garrett N, Huang Y, Innes C, Janes HE, Lazarus E, ... ... Seaton KE, et al. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. Plos One. 15: e0226803. PMID 31999736 DOI: 10.1371/Journal.Pone.0226803 |
0.353 |
|
| 2019 |
Huang Y, Zhang Y, Bailer R, Grunenberg N, Carpp LN, Seaton K, Mayer KH, Ledgerwood J, Corey L, Mascola J, Montefiori D, Gilbert PB. Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of VRC01. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 31855881 DOI: 10.1097/Qai.0000000000002272 |
0.393 |
|
| 2019 |
Neidich SD, Fong Y, Li SS, Geraghty DE, Williamson BD, Young WC, Goodman D, Seaton KE, Shen X, Sawant S, Zhang L, deCamp AC, Blette BS, Shao M, Yates NL, et al. Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. The Journal of Clinical Investigation. PMID 31589165 DOI: 10.1172/Jci126391 |
0.347 |
|
| 2019 |
Cohen YZ, Butler AL, Millard K, Witmer-Pack M, Levin R, Unson-O'Brien C, Patel R, Shimeliovich I, Lorenzi JCC, Horowitz J, Walsh SR, Lin S, Weiner JA, Tse A, Sato A, ... ... Seaton KE, et al. Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study. Plos One. 14: e0219142. PMID 31393868 DOI: 10.1371/Journal.Pone.0219142 |
0.33 |
|
| 2018 |
Bar-On Y, Gruell H, Schoofs T, Pai JA, Nogueira L, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Karagounis T, Cohen YZ, Wyen C, Scholten S, Handl L, ... ... Seaton KE, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nature Medicine. PMID 30258217 DOI: 10.1038/S41591-018-0186-4 |
0.327 |
|
| 2018 |
Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, Lehmann C, Suárez I, Oliveira TY, Lorenzi JCC, Cohen YZ, Wyen C, Kümmerle T, Karagounis T, Lu CL, ... ... Seaton KE, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 561: 479-484. PMID 30258136 DOI: 10.1038/S41586-018-0531-2 |
0.303 |
|
| 2018 |
Huang Y, Karuna S, Carpp LN, Reeves D, Pegu A, Seaton K, Mayer K, Schiffer J, Mascola J, Gilbert PB. Modeling Cumulative Overall Prevention Efficacy for the VRC01 Phase 2b Efficacy Trials. Human Vaccines & Immunotherapeutics. 1-35. PMID 29683765 DOI: 10.1080/21645515.2018.1462640 |
0.34 |
|
| 2018 |
Fong Y, Shen X, Ashley VC, Deal A, Seaton KE, Yu C, Grant SP, Ferrari G, deCamp AC, Bailer RT, Koup RA, Montefiori D, Haynes BF, Sarzotti-Kelsoe M, Graham BS, et al. Vaccine-induced antibody responses modify the association between T-cell immune responses and HIV-1 infection risk in HVTN 505. The Journal of Infectious Diseases. PMID 29325070 DOI: 10.1093/Infdis/Jiy008 |
0.338 |
|
| 2017 |
Seaton KE, Vandergrift NA, Deal AW, Rountree W, Bainbridge J, Grebe E, Anderson DA, Sawant S, Shen X, Yates NL, Denny TN, Liao HX, Haynes BF, Robb ML, Parkin N, et al. Computational analysis of antibody dynamics identifies recent HIV-1 infection. Jci Insight. 2. PMID 29263306 DOI: 10.1172/Jci.Insight.94355 |
0.308 |
|
| 2017 |
Mayer KH, Seaton KE, Huang Y, Grunenberg N, Isaacs A, Allen M, Ledgerwood JE, Frank I, Sobieszczyk ME, Baden LR, Rodriguez B, Van Tieu H, Tomaras GD, Deal A, Goodman D, et al. Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. Plos Medicine. 14: e1002435. PMID 29136037 DOI: 10.1371/Journal.Pmed.1002435 |
0.347 |
|
| 2017 |
Shen X, Basu R, Sawant S, Beaumont D, Kwa SF, LaBranche C, Seaton KE, Yates NL, Montefiori DC, Ferrari G, Wyatt LS, Moss B, Alam SM, Haynes BF, Tomaras GD, et al. HIV-1 gp120 Protein and MVAgp140 Boost Immunogens Increase immunogenicity of a DNA/MVA HIV-1 Vaccine. Journal of Virology. PMID 29021394 DOI: 10.1128/Jvi.01077-17 |
0.322 |
|
| 2017 |
Han Q, Williams WB, Saunders KO, Seaton KE, Wiehe KJ, Vandergrift N, Von Holle T, Trama AM, Parks RJ, Luo K, Gurley TC, Kepler TB, Marshall DJ, Montefiori DC, Sutherland LL, et al. HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces Gp41 Antibody Immunodominance in Rhesus Macaques. Journal of Virology. PMID 28794027 DOI: 10.1128/Jvi.00923-17 |
0.33 |
|
| 2017 |
Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, et al. Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults. Plos One. 12: e0179597. PMID 28727817 DOI: 10.1371/Journal.Pone.0179597 |
0.353 |
|
| 2017 |
Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, Seaton K, Mayer KH, Capparelli E, Corey L, Gilbert PB. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. Mabs. 0. PMID 28368743 DOI: 10.1080/19420862.2017.1311435 |
0.351 |
|
| 2016 |
Andersson AC, Ragonnaud E, Seaton KE, Sawant S, Folgori A, Colloca S, Labranche C, Montefiori DC, Tomaras GD, Holst PJ. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. Vaccine. PMID 27633665 DOI: 10.1016/j.vaccine.2016.08.089 |
0.336 |
|
| 2015 |
Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, ... ... Seaton KE, et al. HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science (New York, N.Y.). 349: aab1253. PMID 26229114 DOI: 10.1126/Science.Aab1253 |
0.336 |
|
| 2015 |
Pollara J, McGuire E, Fouda GG, Rountree W, Eudailey J, Overman RG, Seaton KE, Deal A, Edwards RW, Tegha G, Kamwendo D, Kumwenda J, Nelson JA, Liao HX, Brinkley C, et al. Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1. Journal of Virology. 89: 9952-61. PMID 26202232 DOI: 10.1128/Jvi.01560-15 |
0.302 |
|
| 2015 |
Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, ... ... Seaton KE, et al. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies Science. 349. DOI: 10.1126/science.aab1253 |
0.305 |
|
| 2014 |
Seaton KE, Ballweber L, Lan A, Donathan M, Hughes S, Vojtech L, Moody MA, Liao HX, Haynes BF, Galloway CG, Richardson BA, Karim SA, Dezzutti CS, McElrath MJ, Tomaras GD, et al. HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities. Plos One. 9: e101863. PMID 25054205 DOI: 10.1371/Journal.Pone.0101863 |
0.326 |
|
| 2014 |
Yates NL, Liao HX, Fong Y, deCamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, et al. Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Science Translational Medicine. 6: 228ra39. PMID 24648342 DOI: 10.1126/Scitranslmed.3007730 |
0.356 |
|
| 2014 |
Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, et al. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. The Journal of Infectious Diseases. 210: 99-110. PMID 24403557 DOI: 10.1093/Infdis/Jiu003 |
0.359 |
|
| 2014 |
Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature. 505: 502-8. PMID 24352234 DOI: 10.1038/Nature12893 |
0.347 |
|
| 2011 |
Yates NL, Lucas JT, Nolen TL, Vandergrift NA, Soderberg KA, Seaton KE, Denny TN, Haynes BF, Cohen MS, Tomaras GD. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. Aids (London, England). 25: 2089-97. PMID 21832938 DOI: 10.1097/Qad.0B013E32834B348E |
0.318 |
|
| 2005 |
Seaton K, Smith C. N-myristoyltransferase1 and N-myristoyltransferase2 Exhibit Differential Substrate Specificity for HIV-Gag and HIV-Nef Retrovirology. 2: 88. DOI: 10.1186/1742-4690-2-S1-P88 |
0.306 |
|
| Show low-probability matches. |